PO

Polaris AI Pharma Corp.

A global supplier of generic APIs using AI to accelerate drug development.

041910 | KO

Overview

Corporate Details

ISIN(s):
KR7041910001
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 발안공단로 25, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Polaris AI Pharma Corp., formerly Estechpharma, is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs). The company specializes in the production of generic APIs, with a portfolio of approximately 40 products for various therapeutic areas, including anti-thrombotic, anti-inflammatory, and treatments for gastric ulcers and asthma. A key strategic focus is the integration of artificial intelligence into its research and development pipeline to predict the success of drug candidates and optimize clinical trial designs, thereby accelerating the development process. Polaris AI Pharma serves both domestic and international pharmaceutical markets and engages in joint research for innovative drug delivery systems.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 884.1 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-12 00:00
M&A Activity
[기재정정]주요사항보고서(유형자산양수결정)
Korean 19.8 KB
2025-08-12 00:00
M&A Activity
합병등종료보고서(자산양수도)
Korean 15.7 KB
2025-08-07 00:00
M&A Activity
[기재정정]주요사항보고서(유형자산양수결정)
Korean 20.0 KB
2025-08-01 00:00
Capital/Financing Update
단기차입금증가결정
Korean 9.5 KB
2025-07-07 00:00
M&A Activity
주요사항보고서(유형자산양수결정)
Korean 15.9 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 907.9 KB
2025-03-20 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 18.5 KB
2025-03-12 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 540.9 KB
2025-03-12 00:00
Audit Report / Information
감사보고서제출
Korean 19.4 KB
2025-03-05 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.4 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.9 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 118.6 KB
2024-12-16 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB

Automate Your Workflow. Get a real-time feed of all Polaris AI Pharma Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Polaris AI Pharma Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Polaris AI Pharma Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.